Published • loading... • Updated
Astrazeneca’s breast cancer drug fails late-stage trial
The 1,371-patient SERENA-4 study found only a numerical benefit, raising questions about the drug’s first-line role despite recent accelerated approval.
4 Articles
4 Articles
AstraZeneca’s breast cancer pill fails in late-stage trial - Regional Media News
By Christy Santhosh Sept 11 (Reuters) - AstraZeneca's breast cancer pill failed to meet the main goal of improving progression-free survival in a late-stage trial, the company said on Friday, a week after the treatment received U.S. approval. U.S.-listed shares of AstraZeneca fell 3% in [...]
Astrazeneca’s breast cancer drug fails late-stage trial
Sept 11 (Reuters) - AstraZeneca said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zah...
Coverage Details
Total News Sources4
Leaning Left0Leaning Right1Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
